Navigation Links
Bipartisan Panel of Industry, NGO and Academic Experts Proposes New Rules for Science in Federal Regulation
Date:8/5/2009

Members of scientific advisory committees should be required to disclose to the government and to the public far more information on their backgrounds than is currently the case so the government and the public can evaluate their qualifications and determine whether their service raises any concern about conflicts of interest or bias.
  • Clearer conflict of interest rules. The government should set clear rules about what constitutes a conflict of interest for a member of a scientific advisory committee. The government should distinguish clearly between conflict of interest and bias. Agencies should try not to appoint advisory committee members with conflicts of interest, but if such individuals are appointed, the appointment should be publicly announced and justified. The standard for appointing members with conflicts should be changed to the one used by the National Academy of Sciences. Chairs or co-chairs of committees should never have conflicts.
  • Greater transparency in committee selection might allow a limited number of closed committee meetings. If procedures are put in place to make the selection of advisory committee members more transparent, then the government could consider allowing scientific advisory committees to have a limited number of closed meetings under specific circumstances.
  • Transparency in the use of scientific literature. The process agencies and scientific advisory committees use to review the scientific literature should become more transparent and thorough. They should be explicit about the criteria they are using to determine which scientific papers to review and how those papers are being evaluated, and should pay more attention to the methodology used in cited work. In general, papers that have not been peer reviewed should be treated with skepticism, but they should not be automatically excluded.
  • Legitimate use of Confidential Business Information. The Confidential Business
    '/>"/>

  • SOURCE Bipartisan Policy Center
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine news :

    1. In Case You Missed It: The Washington Posts Ruth Marcus: A Bipartisan Plan on Health Care? Try Two
    2. National Coalition of Front-Line Skilled Nursing Clinicians: Bipartisan Momentum to Stop CMS Medicare Regulation, Subsequent Funding Cuts, Grows in Congress
    3. Health Plans Return to Airwaves in Support of Bipartisan Reform
    4. Oncology Care Quality Improvement Program Introduced by Bipartisan Coalition Dedicated to Better Cancer Care Nationwide
    5. Former Senate Majority Leaders Baker, Daschle and Dole Release Bipartisan Framework for Comprehensive Health Reform
    6. National Restaurant Association Backs Bipartisan Senate Agreement to Empower Consumers Nationwide With More Nutrition Information
    7. Businesses, Unions, Veteran Party Leaders Unite Behind Bipartisan, Consensus Approach to Health Care Reform
    8. Bipartisan Coalition Forms to Call for Chronic Disease to be Key Focus of Health Reform in Indiana and Nationally
    9. Americans United for Life Represents 28 Bipartisan Montana Legislators Arguing Assisted Suicide Not a Right
    10. San Francisco Bay Area Affiliate of Susan G. Komen for the Cure(R) Applauds Introduction of Bipartisan Cancer Alert Act
    11. National Health Experts Launch Bipartisan Coalition to Fight Chronic Disease
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/21/2014)... Portland, OR (PRWEB) December 21, 2014 ... discussing some of the issues and systemic barriers for ... ITU World Paratriathlon Champion. Scheidies has a condition called ... over time. He describes how he adapted his athletic ... to use his success in triathlon to pioneer the ...
    (Date:12/21/2014)... OH (PRWEB) December 21, 2014 As ... men alleging heart attacks, stroke and blood clots from ... to increase, a new study shows that the male ... colon cancer. In a study published in the Proceedings ... researcher, James Amos-Landgraf examined a group of male rats ...
    (Date:12/21/2014)... December 21, 2014 The Oncology Institute of ... the Santa Ana and Whittier offices. The Hope for the ... lives of patients and their families during the holiday season. ... to approximately 70 children between both offices. This event continues ... of Target’s community service team, store managers and assistant managers ...
    (Date:12/20/2014)... 21, 2014 BambooIndustry.com is a professional ... . The business has recently shown its new engineered ... all its bamboo flooring models. , BambooIndustry.com’s customers come ... Asia and more. According to the CEO of the ... very fast in the past few years, and the ...
    (Date:12/20/2014)... 21, 2014 MissyDress, a distinguished special ... prom lovers. The business has drastically cut prices to ... to everyone until Jan. 30, 2015. Many of the ... dresses, V-neck dresses, lace dresses, and more. , A ... there every day. Whether A-line princess prom dresses or ...
    Breaking Medicine News(10 mins):Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2
    ... of ... Hematology 2007, SINGAPORE, Dec. ... most advanced compounds at The American Society of,Hematology 49th Annual Meeting ... and selective JAK2 inhibitor SB1518,highlighted the therapeutic potential of SB1518 for ...
    ... SAN JOSE, Calif., Dec. 10 Human Pheromone ... Company") today announced,today that its Board of Directors ... of common stock, representing approximately 10% of the,current ... open market and,private transactions. The plan sets no ...
    ... 90 mg, * 53% of Patients Treated with 90 mg ... Reduction in the Risk of Death ... Compared to Non-responders, ATLANTA, Dec. 10 ... maturing data,from the Phase 1/2 study investigating the combined use of MGCD0103, ...
    ... (Nasdaq: MLNM ) today reported the presentation ... III clinical trial, comparing,VELCADE and dexamethasone (VcD) to ... by the Intergroupe,Francophone du Myelome (IFM) cooperative group ... at the American Society of Hematology (ASH) 49th,Annual ...
    ... Calls to Quitline, EAGAN, Minn., Dec. 10 ... of Minnesota (Blue Cross), recorded that more of,its members ... enrollment,data reported by Blue Cross, telephone coaching quitline. Stop-smoking,quitline ... in October,2007 -- nearly a 43 percent increase. This ...
    ... the past 30 years,the San Antonio Breast Cancer ... among scientists and clinicians from around the world, ... providing an ideal format for,scientists to present, for ... as,well as other pertinent information, including diagnostic developments., ...
    Cached Medicine News:Health News:S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders 2Health News:S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders 3Health News:Human Pheromone Sciences Announces Stock Repurchase Program 2Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 2Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 3Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 4Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 5Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 6Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 7Health News:VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial 2Health News:VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial 3Health News:VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial 4Health News:VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial 5Health News:VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial 6Health News:Blue Cross' Stop Smoking Phone Coaching Enrollments Jumped in October 2Health News:San Antonio Breast Cancer Symposium December 13th to 16th 2007 2
    (Date:12/19/2014)... WORTH, Texas , December 18, 2014 /PRNewswire/ ... a networked software application/module that is used to ... related images. RIS comprises a patient tracking and ... system. The integration of RIS with HIS and ... used for patient registration and patient scheduling, patient ...
    (Date:12/19/2014)... REDWOOD CITY, Calif., Dec. 18, 2014 ... on the development of medical diagnostics based on ... of gas flow, today announced financial results for ... 30, 2014. "Following the completion of ... well positioned to maximize the recently initiated CoSense® ...
    (Date:12/19/2014)... , Dec. 19, 2014  Eli Lilly and ... Paris: FR0011184241 – ADOC) today announced a worldwide licensing ... BioChaperone Lispro, for treatment in people with type 1 ... proprietary BioChaperone® technology and is currently in Phase Ib ... Lispro with the goal of optimizing glucose levels during ...
    Breaking Medicine Technology:The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
    ... , MORRISTOWN, N.J. , May 24 Watson ... subsidiary, Watson Laboratories, Inc., has received approval from the United States ... for Valacyclovir Hydrochloride tablets, USP, in the 500 and 1000 mg ... to begin shipping the product shortly.   , ...
    ... Genzyme Corp. has signed a consent decree agreeing to correct manufacturing quality violations at ... government $175 million in unlawful profits from the sale of products that ... , , ... , , ...
    Cached Medicine Technology:Watson's Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval 2Watson's Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval 3Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 2Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 3
    BD Vacutainer® Specialty Tubes - Trace Element - Plastic...
    Inquire...
    VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
    BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
    Medicine Products: